Hormone Therapy Risks Vary: Tibolone Linked to Arterial Events
-
By
December 10, 2024
-
2 min
-
1
Tibolone use in menopausal hormone therapy linked to a 52% increased risk of cardiovascular disease.
-
2
Study involved 919,614 women aged 50 to 58 years.
-
3
Different menopausal hormone therapy regimens have heterogeneous cardiovascular risks.
-
4
Tibolone exhibited the highest overall cardiovascular disease risk.
-
5
Need for tailored hormone therapy approaches and further research into progestin-specific effects on cardiovascular outcomes.
-
A recent study indicates that tibolone use in menopausal hormone therapy may be associated with a 52% increased risk of cardiovascular disease. The study, published in BMJ, involved 919,614 women aged 50 to 58 years and highlighted the heterogeneous cardiovascular risks associated with different menopausal hormone therapy regimens. Notably, tibolone exhibited the highest overall cardiovascular disease risk. The findings underscore the need for tailored hormone therapy approaches and further research into progestin-specific effects on cardiovascular outcomes.
-
1
Tibolone use in menopausal hormone therapy linked to a 52% increased risk of cardiovascular disease.
-
2
Study involved 919,614 women aged 50 to 58 years.
-
3
Different menopausal hormone therapy regimens have heterogeneous cardiovascular risks.
-
4
Tibolone exhibited the highest overall cardiovascular disease risk.
-
5
Need for tailored hormone therapy approaches and further research into progestin-specific effects on cardiovascular outcomes.
Listen Tab content
